Long-Term Evaluation of Autologous Serum Eye Drops in Dry Eye Disease

Mélanie Velier,1,2 Justine Champoussin,1 Loic Dambricourt,3 Cecilia Bec,1 Albert Darque,4 Celia Lento,4 Julie Veran,1 Chloé Dumoulin,1 Francoise Dignat-George,2 Thierry David,3 Florence Sabatier,1,2 Jeremy Magalon1,2 1Culture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France; 2Aix-Marseille Univ, C2VN, INSERM 1263, INRAE1260, Marseille, France; 3Ophtalmology Department, CHU Conception, AP-HM, Marseille, France; 4Pharmacy Department, CHU Conception, AP-HM, Marseille, FranceCorrespondence: Mélanie Velier, Culture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France, Tel + 33 0760560415, Email [email protected]: Dry eye disease (DED) remains a therapeutic challenge, particularly in refractory cases. While autologous serum eye drops (ASED) offer short-term benefits, data on their long-term efficacy are scarce. This retrospective longitudinal study evaluated patients treated with ASED for at least three years, with follow-ups at three time points (T1, T2 and T3). Our findings demonstrate that most patients (65.5% at T1, 60% at T2, 65.5% at T3), exhibit a robust and sustained response to ASED therapy over the years, suggesting the potential to identify a responder profile based on early treatment outcomes. Larger-scale studies are needed to clarify the factors underlying this profile, which could ultimately guide personalized therapeutic strategies for DED.Keywords: dry eye disease, autologous serum eye drop, long-term outcomes, ocular surface disease